Q4 FY26 Quarterly Investor Presentation & Webinar
Filed with ASX · · 25 pages · English
Summary by 6ix AI
The presentation reports strong growth in core testing volumes and revenues, with significant year-over-year increases in both categories. The filing emphasizes ongoing progress in both Australian and UK markets, showcasing increased clinician engagement and sales growth.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Watch Microba Life Sciences' latest callMicroba Life Sciences (ASX:MAP) Q4 2025 Earnings Call · Replay · Jul 22, 2025Read the transcript of Microba Life Sciences (ASX:MAP) Q4 2025 Earnings CallMicroba Life Sciences Limited on 6ix
In the deck
Story so far
Earlier from Microba Life Sciences
- Investor presentation - path to cashflow breakeven
- Pause in Trading
- Q3 FY26 Quarterly Investor Presentation & Webinar
- Appendix 4D & FY26 Interim Report
- Q2 FY26 Quarterly Investor Presentation & Webinar
Later from Microba Life Sciences
- Completion of Share Purchase Plan
- Application for quotation of securities - MAP
- Notification regarding unquoted securities - MAP
- Cleansing Notice
- Change of Director's Interest Notice - Prof Ian Frazer
Follow Microba Life Sciences into a list and get an email when it puts out news.
Follow Microba Life Sciences